HUMAN BIOLOGY, AT SCALE
Predicting Drug Succes
Before the Clinic
Navigate Precision Biology develops high-throughput, human-relevant organoid platforms that help the pharmaceutical industry bring better drugs to patients faster.
Today, more than nine in ten drug candidates fail in clinical trials - largely because traditional animal and 2D cell models cannot reliably predict how a treatment will behave in the human body. Navigate tackles this directly. Our proprietary NaviPlate hardware, paired with disease-specific organoids, delivers automation-ready, 384-well screening and preclinical safety testing that reflects authentic human biology. By giving pharmaceutical and biotech partners faster, more affordable, and more predictive insight across discovery, validation, and safety testing, we de-risk decision-making at every stage - reducing late-stage attrition, lowering development costs, and shortening the path from laboratory to clinic.
Our Mission is to make drug development faster, cheaper, and more predictive - replacing unreliable preclinical models with scalable, human-relevant organoid testing that gives every promising therapy the best possible chance of reaching patients.
Our vision is to build a future where every new medicine is validated against authentic human biology before it reaches a single patient - eliminating avoidable late-stage failures, and ensuring that safe, effective therapies reach the people who need them sooner.